22nd Annual
Drug Discovery Summit
01 - 02 June 2021 | London, UK

An invaluable resource for those looking to improve efficiency, increase pipelines and keep up to date with the latest advances. Featuring key insights into protein degradation, AI/ML in drug discovery, and much more

The Drug Discovery Summit features...

Over 400 attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions

A look at the future of drug discovery in new modalities such as biotherapeutics, proteins, cell and genetic based discovery.

The latest updates on the integration of screening approaches in phenotypic and genomics-based discovery, Organ-on-a-chip and 3D modelling, and novel RNA drug targets

Insights into drug discovery strategies & next generation therapeutics, empowering drug discovery with chemical biology, target validation, drug profiling and protein degradation technologies

Successful strategies in compound library development, DNA/RNA encoded libraries, protein to protein interaction, fragment and structured based drug design

A focus on cutting edge tools, including: AI in ADME, big data management, model management, artificial intelligence, machine learning in drug design and AI in chemical synthesis, AI-enabled target ID capabilities, lead identification/optimisation and much more…

Agenda at a Glance

Day One – 01 June 2021

Morning Sessions:

Stream 1: Identification and Validating Novel Targets – Case Study Presentations
Stream 2: Phenotypic Based Discovery & Screening Approaches
Stream 3: New Modalities And Challenging Targets: Targeted Protein Degradation and PROTAC

Afternoon Interactive Sessions:
  • Roundtable Discussions:
    • Identification and Validating Novel Targets
    • New Modalities And Challenging Targets: Targeted Protein Degradation & PROTAC

  • Workshops:
    • Molecular Glue for New Drug Development Workshop
    • E3 Ubiquitin Ligases and Targeted Protein Degradation
    • Overview Of Available Methods To Characterize The Compound – Target Interaction On A Molecular Level Via SPR, MST, ITC and TSA

Day Two – 02 June 2021

Morning Sessions:

Stream 1: New Modalities And Challenging Targets: RNA based Therapeutics
Stream 2: Animal and Disease Modelling, Organoid based Discovery, 3D Media

Afternoon Interactive Sessions:

  • Roundtable Discussions:
    • Target Discovery and Animal Modelling
    • Translational Biomarkers and Patient Engagement
  • Workshop:
    • Development And Identification Of Biomarkers, New Targets And Combination Therapies For Cancer

Live Webinar

Application of In-Vitro and In-Vivo ADME/PK/Expl Tox assays to Support Lead and Candidate Selections

Wednesday, 18th November, 2020
10:00am GMT (UTC+0)

hosted by Lilly Xu, Ph.D. Senior Vice President, DMPK & Exploratory Toxicology Dept, ChemPartner

Download Brochure

Full details regarding the R&D Series are available for download in the Conference Brochure